August 8, 2018 – By Sarah Holford
Analysts expect InflaRx N.V. (NASDAQ:IFRX) to report $-0.40 EPS on August, 16.After having $-0.49 EPS previously, InflaRx N.V.’s analysts see -18.37% EPS growth. The stock decreased 1.17% or $0.38 during the last trading session, reaching $32.11. About 6,522 shares traded. InflaRx N.V. (NASDAQ:IFRX) has 0.00% since August 8, 2017 and is . It has underperformed by 12.57% the S&P500. Some Historical IFRX News: 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6
YEW BIO-PHARM GROUP INC COMMON (OTCMKTS:YEWB) had an increase of 2300% in short interest. YEWB’s SI was 4,800 shares in August as released by FINRA. Its up 2300% from 200 shares previously. With 20,200 avg volume, 0 days are for YEW BIO-PHARM GROUP INC COMMON (OTCMKTS:YEWB)’s short sellers to cover YEWB’s short positions. It closed at $0.25 lastly. It is down 0.00% since August 8, 2017 and is . It has underperformed by 12.57% the S&P500.
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. The company has market cap of $824.01 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Schaeffersresearch.com which released: “3 Healthcare Stocks Making Massive Moves” on July 13, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on July 13, 2018, Streetinsider.com published: “BMO Capital Starts Inflarx NV (IFRX) at Outperform” on July 13, 2018. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Benzinga.com and their article: “30 Stocks Moving In Friday’s Mid-Day Session” published on July 13, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Top Upgrades, Downgrades For July 13, 2018” with publication date: July 13, 2018.
Yew Bio-Pharm Group, Inc., through its subsidiaries, grows and sells yew trees in the PeopleÂ’s Republic of China. The company has market cap of $12.97 million. It operates through five divisions: Traditional Chinese Medicine Raw Materials, Yew Trees, Handicrafts, Wood Ear Mushroom, and Others. It has a 4.24 P/E ratio. The TCM Raw Materials segment engages in the production and sale of raw materials that are used for medicinal application in the pharmaceutical industry.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.